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Predictors of cardiac allograft vasculopathy
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Abstract: CAV remains a leading cause of late graft loss and mortality
among survivors of pediatric heart transplantation. We sought to
deﬁne the incidence of CAV and identify its predictors in pediatric
heart transplant recipients. The OPTN/UNOS database was analyzed
for pediatric recipients who underwent heart transplant between 1987
and 2011. The primary end-point is time from heart transplantation to
development of CAV (CAV-free survival). To identify predictors of
CAV-free survival, demographic and transplant data were analyzed by
the Kaplan–Meier survival method and Cox proportional hazards
regression. Of 5211 pediatric heart transplant recipients with at least
one-yr follow-up, the incidence of CAV at ﬁve, 10, and 15 yr was 13%,
25%, and 54%, respectively. Multivariate analysis found that risk of
CAV was associated with the following variables: Recipient age 1–4 yr
(HR 1.25), 5–9 yr (1.45), 10–18 yr (1.83), donor age >18 yr (1.34),
re-transplantation (2.14), recipient black race (1.55), and donor
cigarette use (1.54). Older recipient and donor age, recipient black race,
donor cigarette use, and re-transplantation were highly associated with
shorter CAV-free survival.
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CAV remains a leading cause of graft loss and
mortality among late survivors of heart
transplantation (1). Despite improvements of
post-transplant management in the current era,
one-third of pediatric patients develop CAV
within 10 yr of transplant (2). Understanding the
risk factors for CAV may lead to earlier diagno-
sis and better management, resulting in longer
graft survival. However, data regarding risk fac-
tors for CAV in children remain scarce. The
PHTS group recently reported CAV risk factors
including older recipient and donor age and early
rejection ( 2 rejections within one yr of trans-
plant) (3). In a report from the ISHLT, the only
identiﬁed risk factor was recipient age ( 11 yr)
(2). Risk factors for the early development of
CAV (within ﬁve yr of transplant) were re-trans-
plant, PRA >10%, congenital heart disease, and
a steroid-free regimen at discharge for mainte-
nance immunosuppression.
The OPTN is the uniﬁed transplant network
operated by a private, non-proﬁt organization
to increase the eﬀectiveness and eﬃciency of
organ sharing and equity in the national system
of organ allocation and increase the supply of
donated organs available for transplantation.
OPTN is administered by the UNOS, which is
a private, non-proﬁt organization that main-
tains a database containing organ transplant
data for every transplant event that occurs in
the United States (4). In our study, we sought
to deﬁne the incidence of CAV and identify its
predictors in pediatric heart transplant recipi-
ents, utilizing this database. Compared to
previous studies, our work references the largest
pediatric transplant data set in the United
States. Furthermore, submission of data to the
OPTN/UNOS database is mandatory. As a
result, these data represent all programs within
the United States. Although data in the OPTN/
UNOS database are not structured speciﬁcally
to be a research database, this large data set
with long patient follow-up enables us to evalu-
Abbreviations: CAV, cardiac allograft vasculopathy; DSA,
donor-speciﬁc antibodies; HR, hazard ratio; ISHLT, Inter-
national Society for Heart Lung Transplantation; OPTN,
Organ Procurement and Transplantation Network; PHTS,
Pediatric Heart Transplant Study; PRA, panel-reactive anti-
body; UNOS, United Network for Organ Sharing.
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ate the incidence and risk factors for CAV in
pediatric heart transplant patients.
Methods
We performed a retrospective analysis of the OPTN/
UNOS database for pediatric patients aged 0–18 yr who
underwent heart transplant between October 1987 and
December 2011 and had at least one-yr follow-up data.
Patients who underwent heart and lung transplantation
were excluded from this study. Patients who underwent
heart re-transplantation were included. The primary end-
point is time from heart transplantation to development of
CAV (CAV-free survival). Because the actual date of CAV
diagnosis is not given in the OPTN/UNOS database, the
date of the annual follow-up immediately following the
CAV diagnosis is used instead. The CAV was not deﬁned
in the OPTN/UNOS database, but rather was deﬁned by
individual transplant centers and did not describe severity.
Our study focus was to identify predictors of CAV using
baseline demographic and immediate pre- and post-trans-
plant data. Age mismatch was deﬁned as donor-to-recipi-
ent age ratio <0.8 or >2.0. HLA and HLA DR
mismatches were deﬁned as  5 loci and two loci mis-
matches, respectively. Signiﬁcant renal insuﬃciency was
deﬁned as serum creatinine >2 mg/dL. In recipients, trans-
fusion between listing and transplant was recorded. Recent
and peak PRA refer to the most recent and peak value
(percent) prior to transplant, respectively. Donor alcohol
use was deﬁned as a history of alcohol dependency. Donor
cigarette use was deﬁned as a history of smoking
>20 pack yr. Early and late rejection was deﬁned as acute
rejection that occurred within and after one yr of trans-
plant, respectively.
Statistical analysis was performed using SAS version 9.2
(Cary, NC, USA). Kaplan–Meier’s product-limit method
and log-rank test were ﬁrst used to analyze CAV-free sur-
vival univariately to examine the association of all potential
risk factors (including interaction items) with CAV. The risk
factors that showed statistically signiﬁcant association
(p < 0.05) with CAV-free survival were then included in
multivariate analysis that utilized Cox proportional hazards
regression along with backward model selection technique
to arrive at our ﬁnal predictive model. Interactions between
risk factors for CAV were tested, and the few that were
included in multivariate analysis were all dropped from the
ﬁnal model. Variables that had more than 50% missing val-
ues were excluded from our analysis. Missing data for those
risk factors included in our ﬁnal model for the prediction of
CAV-free survival were examined, and the degree to which
data was missing appeared to be random. No imputation
for missing values was performed. A p value <0.05 was con-
sidered statistically signiﬁcant.
This study was approved by the Wayne State University
Institutional Review Board. UNOS Standard Analysis and
Research ﬁles provided de-identiﬁed data.
Results
Demographics
Among the 7914 pediatric heart transplant recipi-
ents registered in the database, 2703 patients who
underwent heart–lung transplant or did not have
one-yr follow-up were excluded (Table 1–3) .Of
the 5211 heart transplant recipients analyzed
(Table 1), mean age was 6.5 yr with 44.1% female
and 28.6% <1 yr of age. The most common race
was white (61.5%), followed by black (18.8%).
The most common reason for heart transplant
was cardiomyopathy (48.3%), followed by con-
genital heart disease (42.8%) and re-transplanta-
tion (5.5%). Pretransplant morbidities in
recipients included renal insuﬃciency (2.6%) and
diabetes (0.4%). Recent and peak PRA >10%
prior to transplant were seen in 23.4% and 31.0%
of recipients, respectively.
Table 2 shows the donor characteristics. The
majority of donors was white (62.9%) followed
by black (17.1%). Mean age of donors was
9.3 yr with 42.3% female and 21.3% <1 yr. Mor-
bidities in donors included renal insuﬃciency
(4.8%), diabetes (0.8%), hypertension (1.3%),
cigarette use (4.5%), and alcohol use (2.5%).
Transplant-related characteristics (Table 1)
included the mean ischemic time of 3.5 h with
31.5% >4 h. Early rejection was seen in 24.4% of
recipients and late rejection in 17.6%. Prior to
discharge, a pacemaker was implanted in 1.0%,
and dialysis was required in 2.9% of the
recipients.
Table 1. Recipient and transplant characteristics (N = 5211)
Group Characteristics Percent
Recipient Age (yr)
<1 28.6
1–4 20.4
5–9 13.5
10–18 37.5
Age (mean  s.d.) 6.5  6.2 yr
Race
Black 18.8
White 61.5
Others 19.7
Gender (female) 44.1
Indication for heart transplant
Congenital heart disease 42.8
Cardiomyopathy 48.3
Re-transplant 5.5
Others 3.4
Co-morbidities prior to transplant
Renal insufficiency (Cr >2) 2.6
Dialysis 1.7
Diabetes 0.4
Transfusion (between listing and transplant) 31.9
PRA prior to transplant
Recent PRA >10% 23.4
Peak PRA >10% 31.0
Transplant Ischemic time (>4 h) 31.5
Ischemic time (mean  s.d.) 3.5  1.3 h
Early rejection (within 1 yr) 24.4
Late rejection (after 1 yr) 17.6
Pacemaker implantation before discharge 1.0
Dialysis before discharge 2.9
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Table 3 shows the donor–recipient mismatch
proﬁle. The most common mismatch was overall
HLA locus (60.5%) and HLA DR locus
(55.5%), followed by race (52.0%), gender
(49.0%), age (36.1%), and ABO incompatible
(1.3%).
Predictors of CAV
The estimated incidence of CAV by the Kaplan–
Meier method was 13% at ﬁve yr, 25% at 10 yr,
and 54% at 15 yr after transplant, respectively
(Fig. 1).
Univariate analysis identiﬁed 16 factors associ-
ated with shorter CAV-free survival (Table 4).
These factors included recipient age 1–4, 5–9,
and 10–18 yr, donor age 1–4, 5–9, 10–18, and
>18 yr, re-transplant, recipient black race, recent
and peak PRA >10%, recipient diabetes prior to
transplant, donor alcohol use, donor cigarette
use, early rejection, and transplant year after
2000. The Kaplan–Meier curves comparing
CAV-free survival between the four age groups
of recipients are shown in Fig. 2. No mismatch
(age, gender, race, ABO, and HLA) is associated
with shorter CAV-free survival in univariate
analysis.
Multivariate analysis was performed on all
variables associated with shorter CAV-free sur-
vival in univariate analysis. Factors signiﬁcantly
associated with shorter CAV-free survival in the
ﬁnal model (Table 5) were recipient age 1–4 yr
Table 2. Donor characteristics (N = 5211)
Group Characteristics Percent
Donor Age (yr)
<1 21.3
1–4 24.6
5–9 15.8
10–18 20.5
>18 17.8
Age (mean  s.d.) 9.3  10.3 yr
Race
Black 17.1
White 62.9
Others 20.0
Gender (female) 42.3
Co-morbidities
Renal insufficiency (Cr >2) 4.8
Diabetes 0.8
Hypertension 1.3
Cigarette use 4.5
Alcohol use 2.5
Table 3. Mismatch characteristics between recipients and donors (N = 5211)
Mismatch Age mismatch 36.1%
Gender mismatch 49.0%
Race mismatch 52.0%
ABO blood type
Identical 77.6%
Compatible 21.1%
Incompatible 1.3%
HLA locus mismatch ( 5 loci) 60.5%
DR locus mismatch (2 loci) 55.5%
Fig. 1. Freedom from CAV using Kaplan–Meier survival
analysis in all patients.
Table 4. Univariate analysis of CAV risk factors
Variable HR 95% CI p-Value
Recipient age (reference: <1 yr)
1–4 yr 1.32 1.10–1.59 0.0031
5–9 yr 1.65 1.34–2.01 <0.0001
10–18 yr 2.29 1.97–2.67 <0.0001
Donor age (reference: <1 yr)
1–4 yr 1.43 1.17–1.73 0.0004
5–9 yr 1.44 1.16–1.78 0.0008
10–18 yr 2.28 1.88–2.77 <0.0001
>18 yr 3.14 2.57–3.83 <0.0001
Diagnosis – re-transplant 3.22 2.10–4.93 <0.0001
Recipient race – black 1.70 1.44–1.93 <0.0001
Recent PRA >10% 1.20 1.03–1.39 0.0194
Peak PRA >10% 1.27 1.10–1.47 0.0012
Recipient diabetes 3.42 1.63–7.21 0.0012
Donor alcohol use 2.52 1.88–3.38 <0.0001
Donor cigarette use 2.53 2.03–3.15 <0.0001
Early rejection (<1 yr) 1.69 1.47–1.93 <0.0001
Transplant year after 2000 1.31 1.14–1.51 <0.0001
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Fig. 2. Freedom from CAV using Kaplan–Meier survival
analysis in patients stratiﬁed by age group (age <1, 1–4, 5–9,
and 10–18 yr).
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(HR = 1.25, p = 0.0167), recipient age 5–9 yr
(HR = 1.45, p = 0.0004), recipient age 10–
18 yr (HR = 1.83, p < 0.0001), donor age
>18 yr (HR = 1.34, p = 0.0256), re-transplan-
tation (HR = 2.14, p < 0.0001), recipient
black race (HR = 1.55, p < 0.0001), and
donor cigarette use (HR = 1.54, p = 0.0001).
Impact of coronary allograft vasculopathy on graft survival
Median patient and graft survivals were 17.5 and
12.8 yr, respectively. Median graft survivals for
patients with and without CAV were 10.7 and
14.8 yr (p < 0.001), respectively. The time from
development of CAV to graft loss (deﬁned as
death or re-transplantation) was analyzed by the
Kaplan–Meier survival method (Fig. 3). The
estimated graft survival after CAV development
was 42% at ﬁve yr, 24% at 10 yr, and 16% at
15 yr. There was an initial drop oﬀ at time 0,
indicating that approximately 23.5% of the
patients had CAV diagnosed and graft failure
simultaneously.
Discussion
To our knowledge, this is the largest study
describing predictors of CAV development in
pediatric heart transplant recipients. Our ﬁnal
multivariate model showed that older recipient
age, donor age (>18 yr), recipient black race,
re-transplantation, and donor cigarette use were
highly associated with shorter CAV-free sur-
vival in pediatric heart transplant recipients. In
univariate analysis, donor age <1 yr was associ-
ated with the lowest risk of CAV but became
insigniﬁcant in the ﬁnal model. This was most
likely because donor age was highly correlated
with recipient age. Transplant after year 2000
was associated with shorter CAV-free survival
in univariate analysis. However, this era eﬀect
became insigniﬁcant in multivariate analysis,
most likely because more high-risk heart trans-
plants were performed after year 2000. Degree
of HLA, ABO, age, gender, and race mismatch
were not signiﬁcant predictors of CAV. PRA
>10%, recipient diabetes status, donor alcohol
use, and early rejection were signiﬁcant in uni-
variate analysis but were not in multivariate
analysis. Although cigarette use is likely associ-
ated with older donor age (>18 yr), donor
cigarette use remained signiﬁcant in our
ﬁnal multivariate model even after adjustment
for age. Donor cigarette use may represent
other unmeasured risk for donor pre-existing
coronary artery disease.
Two previous studies describe risk factors for
CAV in pediatric heart transplant recipients. The
PHTS report analyzed data from 751 children
who had coronary angiograms after heart trans-
plant (3). The incidence of angiographic coro-
nary abnormalities at one, three, and ﬁve yr was
2%, 9%, and 17%, respectively. Risk factors for
CAV were recipient age  12 yr, donor age
>30 yr, and early rejection ( 2 times within
one yr of transplant). In a more recent report
from the ISHLT (2), 34% of patients were esti-
mated to develop CAV by 10 yr after transplant.
Freedom from CAV 10 yr after transplant was
diﬀerent among recipient age groups: 73% for
age <1 yr, 73% for 1–10 yr, and 53% for
11–18 yr. Our estimated incidence of CAV was
consistent with previous data. Graft failure after
CAV development was high, conﬁrming that
CAV development aﬀected eventual graft sur-
vival. In our cohort, patients with CAV had a
4.1 yr shorter median graft survival than those
without CAV. We again demonstrated that reci-
pient age, donor age, and re-transplantation were
associated with shorter CAV-free survival. A
new ﬁnding of our study was the signiﬁcant asso-
ciation between recipient black race and shorter
CAV-free survival. Black recipients are known to
have increased risk of long-term graft loss com-
pared with other races (5). Biological and socio-
economic factors may also contribute to a higher
Table 5. Multivariate analysis of CAV risk factors
Variable HR 95% CI p-Value
Recipient age (reference: <1 yr)
1–4 yr 1.25 1.04–1.51 0.0167
5–9 yr 1.45 1.18–1.77 0.0004
10–18 yr 1.83 1.54–2.18 <0.0001
Donor age >18 yr (reference: <18 yr) 1.34 1.11–1.60 0.0256
Diagnosis – re-transplant 2.14 1.70–2.70 <0.0001
Recipient race – black 1.55 1.33–1.80 <0.0001
Donor cigarette use 1.54 1.20–1.98 0.0001
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Fig. 3. Graft survival after diagnosis of CAV by the
Kaplan–Meier survival method in all patients. *Number of
patients who were still CAV-free minus those that are
censored out.
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risk of rejection, resulting in worse post-trans-
plant graft survival in this group (6).
One of our study questions was to examine the
association between HLA mismatch and CAV.
HLA mismatch can result in development of
DSA, which can contribute to the development
of CAV by antibody-mediated rejection. CAV-
free survival was not associated with overall
HLA mismatch level or HLA DR mismatch at
the time of transplant. The presence of DSA is
not available in the OPTN/UNOS database.
Traditional and non-traditional risk factors
for CAV have been described primarily in adults
(7). Traditional risk factors include hyperlipid-
emia, diabetes, and hypertension; non-traditional
risk factors include cytomegalovirus infection,
HLA mismatch, antibody-mediated rejection,
and mode of donor brain death. Because graft
survival is 48% at ﬁve yr after the diagnosis of
CAV (2), the prevention of CAV is critical to
improved graft survival. Transplant recipients
with known risk factors for CAV should be mon-
itored closely and receive early intervention to
reduce CAV risk.
Limitation
The advantage of our study is that submission of
data to the OPTN/UNOS database is mandatory
for transplant registrants and recipients, thus
increasing the statistical power to identify risk
factors for rare events such as CAV. The OPTN/
UNOS database is not structured speciﬁcally to
be a research database and thus has inherent lim-
itations. There was no uniform deﬁnition or
monitoring for CAV, and no CAV severity given.
Accordingly, there may be potential misclassiﬁ-
cation bias. The incidence of CAV is dependent
to some extent on the surveillance strategy of
individual center. Some putative CAV variables
such as hypertension, cytomegalovirus infection,
Epstein–Barr virus infection, dyslipidemia, and
crossmatch at transplant as well as antilipid and
antihypertensive medications were not included
in our analysis because these data were not
routinely available for all patients in the data-
base. In terms of acute rejection, antibody-medi-
ated and cellular rejection was not separately
recorded, and no variables describing the fre-
quency or severity of acute rejection episodes
were available in the database. Because of the
wide variety and change of immunosuppressive
agents and regimen over the post-transplant
course, the eﬀect of each agent and regimen on
CAV development could not be accurately
assessed in our model.
Conclusions
Older recipient and donor age, recipient black
race, donor cigarette use, and re-transplantation
were highly associated with shorter time from
transplantation to development of CAV in pedi-
atric heart transplant recipients. The identiﬁca-
tion of higher risk recipients may urge transplant
providers to more closely monitor these patients
in terms of other modiﬁable traditional risk fac-
tors, thus potentially reducing incidence/severity
of CAV, and increasing graft survival.
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